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Abstract

The overgrowth and disequilibrium of pathogenic microorganism species both native
and non-native to the oral cavity can manifest into a variety of different oral diseases,
pathologies, and afflictions in humans, including dental caries, gingivitis, pharyngitis,
halitosis, and oral candidiasis. Two bacterial strains with clinically-significant probiotic
applications in curtailing the pathogenic bacterial growth involved in these conditions are
Streptococcus salivarius strain K12 and Streptococcus salivarius strain M18. To
summarize the most up-to-date in vitro, in vivo, and clinical research findings,
administration of these S. salivarius strains typically in the form of probiotic lozenges
results in colonization, reduction in inflammatory measures, and marked alterations to
physical structure & gene expression of the oral epithelial cells of the pharynx, tongue,
and buccal membrane. While K12 and M18’s reduction of pharyngitis and halitosis has
been largely attributed to bacteriocin production, the probiotic strains utilize different
modes of action to reduce other oral pathologies. The prevention of dental caries,
gingivitis and oral candidiasis appears to be ultimately influenced by K12 and M18’s
production of dextranase & urease, reduction of inflammatory cytokines, and direct
physical attachment to pathogens, respectively. In addition to conferring several oral
health benefits, these S. salivarius strains have been proven extremely safe for human
consumption in clinical trials and have the potential for universal application as an
alternative treatment to antibiotics in the aforesaid oral pathologies.
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Introduction

The well-defined interconnectivity between oral cavity health and systemic bodily
health has earned the mouth the rightly-deserved title “the gateway to the body”. Oral
health plays a variety of roles in maintaining overall systemic health and therefore, good
oral health is essential for the well-being of humans. A significant contributor to oral
health status is the vast microbiome of bacteria, fungi, and other organisms that reside
within the oral cavity. At a given point in time, approximately 700 different taxa of
bacterial species simultaneously inhabit the human mouth.1 Some of these taxa are
“good” bacteria that are capable of providing benefits to the oral cavity (and to the body
as a whole), and some of these “bad” bacterial taxa exert detrimental effects. The “bad”
bacteria can be problematic to humans by engendering dental caries, periodontal disease,
strep throat, and a wide range of other diseases. The “good” bacteria have a host of
beneficial effects on humans, including immunomodulation and prevention of pathogen
colonization.1 Certain “good” microorganisms can dampen the effects of “bad” microbes,
while providing a host of positive effects on the oral cavity and body as a whole.
As a result of the beneficial qualities of certain “good” bacterial species,
microbiologists conceived the notion of utilizing supplements of these species for human
consumption. A discrete dose of viable “good” bacteria which confers benefits to the
individual receiving the supplement is referred as a probiotic. One particularly important
benefit of probiotics is the ability to treat inflammatory diseases and infections. Different
probiotics can exert beneficial effects in specific targeted areas along the digestive tract,
beginning at the oral cavity and ending at the colon. The majority of primary research
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focuses on the gastrointestinal benefits of probiotics, but probiotics can indeed exert a
wide array of benefits on other parts of the body, such as the oral cavity.2 Compared to
their gastrointestinal probiotic counterparts, these “oral probiotics” are relatively new
probiotic formulations capable of combatting “bad” bacteria and disease in the oral
region, which is extremely fundamental from a health perspective.
Of particular importance and the subject of extensive research, one “good” bacterial
species that is utilized as a commercial oral probiotic is Streptococcus salivarius. This
species is a spherical, gram positive, oxidase negative, and catalase negative bacterium.3
S. salivarius is one of the earliest colonizers of the epithelial lining of the human mouth
and nasopharynx.1 The bacterium colonizes the tongue dorsum and pharyngeal mucosa of
infants, who acquire the bacterium from their mother within two days after birth.4 The
two most well-studied strains of S. salivarius that are currently employed as probiotics
are strains K12 and M18. S. salivarius K12 was first isolated from the saliva of a healthy
child, and has been utilized as a commercial probiotic in New Zealand for over a decade.5
K12 produces salivaricin A2 and salivaricin B, two bacteriocins that effectively inhibit
phylogenetically related bacterial species.6 In the human population, approximately 2% of
children naturally possess S. salivarius strains that produce both salivaricin A and
salivaricin B, which corresponds to the strain K12 bacteriocin profile.6 Due to K12’s
bacteriocin profile that effectively inhibited strep-throat-causing bacterial species in
preliminary studies, BLIS K12 was commercially developed and thus became the first
S. salivarius K12 oral probiotic to specifically target oral health. Another well-studied
strain of S. salivarius is strain M18. This strain exhibits a markedly different bacteriocin
profile compared to strain K12 and effectively secretes the bacteriocins A2, 9, MPS and
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M.7 Due to M18’s ability to inhibit dental caries-causing pathogens, BLIS M18, which
utilizes active strains of S. salivarius M18, was commercially developed to focus on
dental health issues that K12 seemingly cannot address.7
When K12 and M18 are first introduced into the oral cavity typically in the form of a
probiotic lozenge, they must colonize specific oral regions and be tolerated by the human
host. Once the bacteria establish themselves, they can then confer their individually
distinct oral health benefits to the human host. This primary research literature review
will synthesize and analyze the most current research on these two commercially-utilized
probiotic strains by discussing the colonization pattern and commensal relationship of
K12 and oral epithelial cells, the clinical benefits that each strain confers to humans and
the proposed mechanisms, oral probiotic safety and future implications.
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Colonization of the Oral Cavity by S. salivarius K12 & M18

Before S. salivarius K12 and M18 can exert their beneficial oral health effects, they
must first effectively colonize the oral cavity. To begin their colonization of the oral
cavity, individual S. salivarius K12 cells must adhere to oral epithelial cells and then
rapidly reproduce to form colonies. Orf166, an open reading frame that is present on
K12’s megaplasmid, encodes a cell-surface protein, which ultimately enables this strain
to attach to HEp-2 epithelial cells, along with the help of other adhesion factors.8 Once S.
salivarius K12 attaches, there is a remodeling of the host epithelial lining to facilitate the
commensal interaction between the bacterial and host cell.1 Specific epithelial cell
cytoskeleton-related and adhesion-related genes are upregulated and downregulated,
suggesting structural and adhesive changes in epithelial cells that can strengthen the cells’
interactions with K12.1 Once BLIS K12 has adhered to the epithelial lining, it colonizes
areas along the upper respiratory tracts of children, including the oral cavity,
nasopharynx, and adenoid tissues.9 Within the oral cavity itself, the colonization sites of
S. salivarius K12 are primarily the pharynx, tongue, and buccal membrane.4 K12
colonizes the pharynx to a greater degree than the tongue and buccal membrane,
reproducing to approximately 1.24x105 CFU compared to 1.3x104 CFU and 4.6x104
CFU, respectively.4 Even so, the colonies make up only less than 1% of the entire
population of bacterial flora in these particular regions.4 Following human consumption
of K12 lozenges, the strain can last in these areas for as long as three weeks, but the
CFUs tend to decrease dramatically after a week.4 In the saliva, S. salivarius can be
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present in concentrations as high as 1x107 CFU/mL, which greatly surpasses the colonial
concentrations in the other oral regions.7
Similar to the patterns of colonization by K12, the colonization of the oral cavity by S.
salivarius M18 is dose-dependent.8 When larger dosages are administered, an increased
number of M18 bacteria are retained over a period of time.8 However, when a persistent
lower dosage is administered, there is no cumulative increase in the concentration of M18
in the oral cavity.8 Upon M18 colonization of the oral cavity, there is little to no
widespread perturbation of the oral microbiome.8 Instead of large-scale shifts in bacterial
composition, the proportions of bacterial species only shift slightly.8 This experimental
data supports the clinical safety of the strain, as extensive disturbances in the microbiota
of healthy subjects are not desirable; significant alterations could potentially yield
negative impacts on the probiotic consumers.
Research shows that the form of probiotic bacteria that is consumed does indeed have
an effect on rates of oral bacterial colonization. For example, BLIS K12 Throat Guard,
a lozenge containing strain K12, demonstrates an 80% effectiveness in colonizing the
oral cavity of those who consume the probiotic.10 However, when the consumers ingest
the non-lozenge powdered formula of the probiotic, the effectiveness greatly diminishes
to 33%.10 The reduced efficacy of the powdered form can be attributed to a reduced oral
cavity exposure time compared to when the lozenge form is administered.10 Therefore,
the apparent method for an efficacious administration of S. salivarius K12 appears to be
the probiotic lozenge form, as opposed to the powdered variation.

9

The Commensal Relationship of S. salivarius K12 & Oral
Epithelial Cells

Once the strains of S. salivarius have colonized the oral cavity, the oral epithelial cell
structure and gene regulation are influenced by strain K12 to facilitate a commensal
relationship. S. salivarius K12’s probiotic quality can be attributed to its unique
interactions with oral epithelial cells that modulate physiological responses and innate
defenses. Through its interactions with the host cells, S. salivarius promotes oral health,
maintains homeostasis by reducing inflammation and pathogen-induced apoptosis, and
allows itself to be tolerated by the human host.1 S. salivarius K12 accomplishes these
actions by inhibiting a pro-inflammatory response, stimulating an anti-inflammatory
response, and modulating genes related to adhesion & homeostasis.1
S. salivarius K12 downregulates the inflammatory response by inhibiting the NF-B
pathway in human bronchial epithelial cells (16HBE14O-).1 K12 does not initiate the
synthesis of pro-inflammatory cytokines or chemokines. In fact, the strain actually
decreases normal interleukin-8 (IL-8) secretion, as well as its secretion when epithelial
cells are exposed to pathogenic Pseudomonas aeruginosa, Salmonella serovar
Typhimurium flagellin, and the immunomodulatory host defense peptide LL-27.1
Growth-related oncogene alpha (Gro), which is involved in leukocyte recruitment and
proliferation, was similarly downregulated when exposed to flagellin in the presence of
K12 cells.1 Taken together, the downregulation of these processes illustrates the K12induced reduction of the inflammatory response
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In addition to inhibiting a pro-inflammatory response, K12 also stimulates an antiinflammatory response. When human bronchial epithelial cells are exposed to S.
salivarius K12 and gene expression in these epithelial cells is analyzed, NF-Bstimulated binding sites in the promoter regions of K12-modulated genes are
underrepresented.1 This underrepresentation ultimately leads to a response that is antiinflammatory. In addition, the nicotinic acetylcholine pathway was overrepresented.1
This pathway has the potential for anti-inflammatory effects through its suppression of
IB phosphorylation and NF-B-induced transcription.1 Furthermore, the binding sites
for CREB, a transcription factor that has been implicated in anti-inflammation, were
significantly overrepresented in cells treated with K12.1 Additional expression data
demonstrates an underexpression of proapoptotic FAS signaling and transforming growth
factor  pathways, both of which have anti-inflammatory consequences.1
Finally, K12 modulates homeostatic genes involved in transcription, translation,
protein trafficking, exocytosis, nucleoside metabolism, and phosphate metabolism.1 As
previously discussed, the expression of genes involved with the cytoskeleton and
adhesion are also modulated by strain K12. Based on the collective experimental data, the
gene expression patterns suggest an attenuated epithelial cell inflammatory response in
response to S. salivarius. In conclusion, K12 modulates genes involved in the innate
response pathways and epithelial cell homeostasis to ensure that it is tolerated by the
human host.
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Oral Health Benefits of S. salivarius K12 & M18 Probiotics

After becoming established in the oral cavity, S. salivarius K12 and M18 can exert
their beneficial probiotic health effects on the human host. Both the K12 and M18 strains
have demonstrated the potential to provide a wide array of health benefits to human hosts
based on in vitro, in vivo, and clinical experimental investigations. One particularly
significant benefit is the reduction of oral diseases, maladies, and afflictions including:
(1) pharyngotonsillitis, pharyngitis & tonsillitis, (2) dental caries, (3) gingivitis &
periodontitis, (4) halitosis, and (5) oral candidiasis.
(1) Pharyngotonsillitis, Pharyngitis & Tonsillitis
Pharyngitis and tonsillitis both involve the symptoms of redness, pain, and
inflammation of the throat and tonsils, respectively. Group A beta-hemolytic
streptococci are typically the culprit of bacterial-induced pharynigitis.2 The
bacterium responsible for the large majority of bacterial pharyngitis cases is
Streptococcus pyogenes, and if untreated, infection can result in rheumatic fever,
deep space abscesses, and toxic shock.9 Some cases of pharyngitis can become
chronic, with recurrent episodes of infection.9 When patients diagnosed with
recurrent pharyngitis consume Bactoblis, which contains S. salivarius K12, they
exhibit an 80-96% reduction in the number of episodes of streptococcal
pharyngitis and/or tonsillitis infections during a 90-day treatment regimen.2, 9, 11
Following the 90 day regimen, they similarly exhibit a 60% reduction in the
number of reports of pharyngitis in the six month period following the Bactoblis
regimen.9 Retrospective studies of children with recurrent pharyngitis who were
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treated with S. salivarius K12 Bactoblis demonstrate the same trend of a
significant reduction in pharyngitis cases throughout the course of treatment and
for the following 9 months post-treatment.12 In addition to preventing -hemolytic
streptococcal pharyngeal infections, one study reports an 80% reduction in viral
pharyngeal infections.11 This result should be further investigated to explore the
potential for K12 in reducing non-bacterial infections.
The prevention of S. pyogenes infections can be attributed to the production of
lantibiotics, a specific classification of antimicrobial peptides that contain
lanthionine.13 These lantibiotics are a subgroup of bacteriocins, which interfere
with the growth of bacteria that are phylogenetically-similar to S. salivarius.12
Strain K12 is capable of producing two lantibiotics: salivaricin A2 (SalA2) and
salivaricin B (SboB).14 Although salivaricin A2 and salivaricin B are
simultaneously produced in this particular strain of S. salivarius, they are
unrelated peptides.14 SalA2 is a 2,368-Da peptide that has two amino acid
substitutions at position 4 (S  T) and at position 7 (I  F) that differentiate this
variant from salivaricin A.14 SboB, a 2,740-Da peptide, is encoded by a cluster of
eight genes that is flanked by large inverted repeat sequences.13 Salivaricin B’s
mode of action in reducing S. pyogenes is bactericidal.15 It is a broad-spectrum
lantibiotic, capable of inhibiting the growth of Streptococcus sanguinis,
Streptococcus equisimilis, Streptococcus agalactiae, Streptococcus pneumoniae,
Streptococcus sobrinus, Corynebacterium dyptheriae, Lactobacillus casei,
Stomatococcus mucilagenosus, and Moraxella catarrhalis.15 The loci of the genes
that encode salivaricin A2 and salivaricin B are located nearly adjacent to one
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another on a 190-kb megaplasmid- the separation is only about 7.5-kb.13 K12 can
transfer its megaplasmid to different S. salivarius strains in subjects who are K12colonized, indicating that the genes encoding salivaricin A2 and B are indeed
transmissible.15 When the megaplasmid is removed from a K12 bacterium, there is
no longer an antagonistic influence on the growth of S. pyogenes.2 Altogether, the
data demonstrates that S. salivarius strain K12’s secreted lantibiotics are capable
of inhibiting this prominent pharyngitis-causing bacterial species.2
While K12 produces A2 and B, S. salivarius strain M18 produces salivaricin
A2, 9, MPS, and M.7 Salivaricin A2, MPS, and 9 are all megaplasmid-encoded
and capable of inhibiting S. pyogenes.7 While MPS, a 60-kDa peptide, has an
inhibitory effect specific to S. pyogenes, A2 and 9 are both broader in their
actions, capable of inhibiting additional respiratory tract pathogens.7 Salivaricin
M is responsible for inhibiting mutans streptococci and its expression is
chromosomally-regulated.7
S. salivarius K12 was the first bacterium known to produce two distinct
lantibiotics.13 As production of these lantibiotics is energetically costly, producing
multiple bacteriocins indicates the important role of S. salivarius in maintaining
microbiological balance in the oral cavity.13 The K12 bacteriocins have strong in
vitro inhibitory activity against S. pyogenes, which provides a means of reducing
the presence of this pharyngitis and tonsillitis-causing microbe in the oral cavity.7
In addition to the bacteriocin-based mode of inhibition, K12 cells bind strongly to
human epithelial cells (HEp-2 cells) and competitively interfere with S.
pyogenes’s binding to this same cell line.7
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(2) Dental Caries
Dental caries is one of the most common childhood diseases and is
characterized by the breakdown of tooth enamel and dentin due to “bad”
bacteria.16 These “bad” bacteria release organic acids that reduce the pH of the
oral cavity. The lowered environmental pH causes the dissolution of
hydroxyapatite matrices of enamel and dentin.17 Typically, a combination of
mutans streptococci (particularly Streptococcus mutans and Streptococcus
sobrinus) and individual factors (i.e. saliva composition, fluoride exposure,
dietary & hygiene habits, etc.), can stimulate this decrease in the pH of the oral
cavity.16
Treatment with S. salivarius M18 effectively reduces a patient’s risk of
developing dental caries through a molecular mechanism that increases oral pH
and reduces plaque formation. In one study, the risk of a patient developing dental
caries is assessed through Cariogram, a software program that identifies the
relative risk of developing caries based on nine pathological and protective
factors, coupled with the expertise of the dentist.16 When children who are at
“high risk” for developing caries are treated with Carioblis, an oral probiotic
containing S. salivarius M18, they are less likely to develop dental caries based
on the Cariogram outcome following a 90-day regimen.16 In the untreated control
group, on average, there was a 20% chance of avoiding cavities at day zero and
this percentage only slightly increased to 37% after a period of 90 days.16 In the
M18-treated group, at day zero, subjects had an average of a 20% chance of
avoiding new cavities (which mirrors that of the control group), while this
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percentage significantly increased to 70% after the 90 day treatment.16 Not only
was the overall chance of developing dental caries significantly reduced by the
M18 treatment regimen, but the amount of plaque and mutans streptococci both
decreased by approximately 50% and 75%, respectively.16 The untreated control
group did not exhibit any differences in concentration of plaque or mutans
streptococci.
The treatment of dental caries using S. salivarius M18 probiotics appears to
yield greater benefit and effectiveness in a certain group of patients. Participants
who have high plaque scores receive a greater degree of benefit from M18
treatment, as they exhibit superior levels of plaque reduction.18 Additionally,
patients who are colonized by S. salivarius M18 demonstrate greater plaque
reduction compared to those subjects who were not colonized and were merely
exposed to the bacterial probiotics.18 Similarly, those patients who are M18colonized exhibit a greater reduction of S. mutans.18 Studies indicate that higher
levels of colonization result in a greater reduction of this caries-causing bacterium
in saliva, and thus an overall reduction in the development of dental caries itself.18
This significantly decreased risk of developing dental caries due to a 90-day S.
salivarius M18 regimen can be attributed to several proteins produced by the
strain. As previously discussed, M18 releases salivaricin M, which limits the
growth of the caries-causing bacterial species, S. mutans and S. sobrinus.16
Moreover, the strain secretes dextranase and urease. While dextranase catalyzes
the breakdown of dextran, urease facilitates the hydrolysis of urea.16 As dental
plaques are rich in dextran, dextranase can aid in solubilizing the plaques that
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contribute to the breakdown of tooth enamel and dentin. Similarly, urease can
increase the pH of saliva by breaking down urea into carbon dioxide and
ammonia, and thus prevent hydroxyapatite dissolution. Therefore, dextranase and
urease are two M18 enzymes that are effective in decreasing rates of dental caries
by reducing plaque accumulation and plaque acidification, respectively.16
(3) Gingivitis & Periodontitis
Gingivitis is characterized by the inflammation of the gingiva as a result of
excess plaque, while periodontitis is a more severe form of gum disease that
involves the gingiva pulling away from the teeth. Periodontal disease can be
caused by several bacterial species, including Porphyromonas gingivalis,
Aggregatibacter actinomycetemcomitans, and Fusobacterium nucleatum.3 These
bacteria implicated in gingivitis and periodontitis induce inflammation of the
gums by releasing multiple cytokines, including IL-6 and IL-8 .3 Another
contribution to the development of gingivitis and periodontitis is the accumulation
of plaque on the surfaces of human dentition, especially near the gingiva.18
When BLIS M18 lozenges are administered to subjects, measures of gingivitis
including supragingival plaque, gingival inflammation, sulcular bleeding, and
probing pocket depth using a Williams periodontal probe are all significantly
reduced compared to baseline levels prior to consuming the probiotic.19 After a
cease in the regimen, there is an increase in all these parameters, such as an
increased number of bleeding sites.19 Both strains K12 and M18 are capable of
reducing P. gingivalis, A. actinomycetemcomitans, and F. nucleatum-induced IL6 and IL-8 levels, which are important indicators of the level of inflammation in
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periodontal disease.3 The previously described ability of K12 to reduce the
production of cytokines when it is commensally associated with oral epithelial
cells, coupled with its ability to reduce cytokine levels induced by gingivitiscausing bacterial species, further supports K12’s anti-inflammatory role in the
oral cavity. Moreover, as S. salivarius M18 confers plaque reduction to human
hosts, this can be an additional means of reducing the gingival inflammation
involved in gingivitis.18 In summary, the probiotics M18 and K12 reduce levels of
gingival inflammation and plaque, which in turn leads to a reduction in severity
measures of gingivitis and periodontitis.
(4) Halitosis
Although halitosis, commonly known as oral malodor or “bad breath”, is not a
medical problem, it is a generally undesirable oral hygiene concern.20 Halitosis is
prominently treated by using antimicrobial agents or mechanical devices to reduce
bacterial populations that particularly inhabit the lingual region of the oral
cavity.21 Halitosis is primarily caused by the presence of volatile sulfur
compounds (VSC), sulfur-containing metabolic by-products of anaerobic
bacteria.20 S. salivarius itself does not produce large quantities of VSCs, and
therefore has an extremely minimal contribution to oral malodor.20 When
lozenges containing S. salivarius K12 are consumed for a week by human
subjects with high VSC levels, their VSC levels were significantly reduced in
85% of test subjects, indicating a reduction in this important marker of halitosis.20
Moreover, there was the greatest bacterial composition change in the group that
received S. salivarius lozenges, and K12 was detected in the saliva samples of
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subjects after 7 and 14 days.20 The subjects that had larger quantities of K12
present in saliva samples exhibited the greatest reduction in VSC levels.
Even if the host is not colonized by K12, the bacteria are still capable of
increasing the lantibiotic concentrations in saliva, which can be effective in
reducing halitosis-causing bacterial species. In vitro, K12 reduces the growth of
black-pigmented bacteria and several Gram-positive bacterial species implicated
in halitosis by producing salivaricin A and salivaricin B.20 The Gram-positive
bacteria that are implicated in halitosis that S. salivarius inhibits include:
Streptococcus anginosis T29, Eubacterium saburreum, Micromonas micros,
Atopobium parvulum, Eubacterium sulci, Parvimonas micra, and Solobacterium
moorei.22 Although K12 antagonizes numerous Gram-positive bacteria that cause
halitosis, there are no known Gram-negative bacteria that are effectively
inhibited.22 When halitosis-causing bacterial species are reduced and replaced
with non-halitosis-causing bacterial species (such as S. salivarius K12), this
serves as a viable means to reduce halitosis.
As current treatments for halitosis tend to have short-term results, with VSCproducing bacteria quickly repopulating the oral cavity, there is a present need for
a longer-term solution. Since a majority of subjects maintained reduced VSC
levels for two-weeks following consumption of K12 lozenges, there is a potential
role for K12 as a longer-term treatment solution for halitosis.21 As the literature
supporting the role of S. salivarius K12 in long-term reduction of halitosis is
relatively minimal, more research will be needed to determine if K12 is a viable
treatment measure.
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(5) Oral Candidiasis
The overgrowth of Candida albicans, a common yeast species, can result in
oral pathologies such as oral candidiasis, which is more commonly referred to as
thrush. Thrush causes severe inflammation as well as the potential for infection,
especially in populations of individuals who are immunosuppressed.23 In vitro,
K12 prevents the adherence of C. albicans to a plastic petri dish substratum.23 In
vivo administration of S. salivarius K12 in a mouse model demonstrates a dosedependent reduction in oral candidiasis symptomology. Although administered
dosages of K12 do not completely eradicate populations of C. albicans, the mice
tongues have fewer lesions, less fungal growth, and reduced pathogenicity
(decreased fungal mycelial invasion of tongue epithelium).23 Therefore, the
overall effect of K12 is the inhibition of C. albicans colonization.
The reduction of oral candidiasis by S. salivarius K12 can be attributed not to a
direct fungicidal effect, but to the bacterium’s ability to directly bind to hyphae of
C. albicans.23 The probiotic microbe surrounds and attaches to C. albicans during
fungal germ tube formation and mycelial expansion, which reduces the
pathogenic yeast’s ability to adhere to substrates.23 K12 preferentially binds to the
fungal mycelia but not to individual yeast cells themselves. As many of the
antimicrobial effects of strain K12 are due to its bacteriocin production, the direct
yeast cell-to-bacterial cell contact is seemingly a unique mode of inhibition. S.
salivarius K12 thus acts by preventing adhesion of C. albicans to epithelial
surfaces in the oral cavity, which causes the yeast to be ingested down the
esophagus to eventually be excreted by the human host.23
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Safety Assessment of BLIS K12 Oral Probiotics

Based on its performance in clinical trials and in vitro tests, S. salivarius appears to be
a highly safe bacterium for human consumption as a probiotic. When an antibiogram test
for the species was performed using the antibiotic disk sensitivity method, strain K12
demonstrated sensitivity to many commonly used antibiotics, such as penicillin and
amoxicillin.1 However, the strain exhibited moderate levels of resistance to gentamicin
and ofloxacin, with zones of inhibition in the range of 14-18 mm.1 Overall, the bacterium
lacks resistance to any clinically-significant antibiotics, indicating that even in obscure
cases of S. salivarius infection, it can be easily combatted by common antibiotic
treatments. Using two commercially-available microorganism identification tests (the
API 20 Strep and API 50CH tests), which can help map metabolic profiles of different
microbes, none of the fermentation or enzymatic reactions that are investigated in these
commercial tests indicate that strain K12 would have a hazardous effect on humans.1 The
organism does not produce any hazardous metabolic by-products, such as D-lactate.10
When this bacterium underwent blood cell lysis testing on human blood agar, sheep
blood agar, and buffered CNA-P agar, there was no hemolytic activity observed in any of
these mediums.1 In testing the presence of virulence factors in strain K12 using PCR and
Southern hybridization, there were no streptococcal virulence determinants or factor
genes detected in K12.1 At this point in time, there is no genome sequence of S.
salivarius available. A genome sequence could provide a more in-depth analysis of
virulence factors in this bacterial species and is one limitation that yields some
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uncertainty in definitively stating that S. salivarius K12 lacks streptococcal virulence
factors altogether.
In clinical-based safety assessment studies, human subjects consumed lozenges
containing S. salivarius K12 at regular intervals and reported no adverse symptoms over
the course of 28 days. There was also no significant change in the levels of S. salivarius
or facultative anaerobic bacteria in saliva samples of subjects before and after the
probiotic regimen.1 Additionally, BLIS K12 was tested to identify its potential to
induce point mutations in microorganisms. A bacterial reverse mutation test was
performed at varied bacterial concentrations, and the bacterium appeared to lack any
mutagenicity. In the short-term, even when administered orally to rats at high dosages of
K12 (5 g/kg), there are no apparent adverse effects caused by the strain. There was no
sign of cancer, tissue abnormality, or infection acutely after 14 days.10 As the typical dose
of S. salivarius K12 is 7.5 mg/kg, there is little possibility of toxic effects in humans.10
Using several health indicators, including gross pathology, biochemical tests,
hematology, body & organ weight, histopathology, and urinalysis, in sub-acute testing
(28 days), there similarly was no toxic effect in rats, even at the highest doses.10 In other
clinical safety assessment studies, 100 healthy adults consumed lozenges with K12
concentrations of 1x109 CFU and it was determined that after colonization, the bacteria’s
persistence in the oral cavity was not at levels higher than subjects who naturally possess
strain K12.10 A final validation of the virtually non-existent toxicity and side-effects is
the fact that hundreds of thousands of doses have been administered in New Zealand
(mainly in children) in the past fifteen years and there have been no apparent sideeffects.6 There have been no reports of infections caused by S. salivarius strain K12 or
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M18, and reports of infection by other S. salivarius strains are generally quite
uncommon. Between the in vitro and clinical investigations, the data indicates that strain
K12 has a low pathogenic potential and a minimal chance of causing disease in humans.
There is essentially no indication that BLIS K12 probiotics have a negative impact on
humans, and therefore, they appear to be extremely safe for human consumption.
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Future of S. salivarius Strain K12 & M18 Oral Probiotics

In the field of probiotic research, there is a present need for more information about
the relatively novel branch of oral probiotics. As there still is a rather small pool of
research about S. salivarius strain K12 and M18, future clinical testing will be necessary
to confirm the roles of these probiotics in terms of practical clinical application. While
the majority of the oral probiotic research focuses on K12, more research should be
conducted on M18 and other S. salivarius strains that provide oral health benefits.
Similarly, much of the current research focuses on the overall effects of K12 and M18 on
oral health measures, rather than the mechanisms that are the underlying cause of these
effects; this is one area that particularly needs to be investigated in further detail. Of the
studies presented in this review, the majority have a small sample size. To improve the
validity of the data and the accuracy of conclusions that can be drawn from the research,
more extensive studies should be conducted that are double-blinded, placebo-controlled,
and have large pools of participants who are randomly assigned to an experimental or
control group.
Despite the limitations of the present studies on the subject, there are several
socioeconomic implications in the treatment of the described infections, maladies, and
afflictions through the use of S. salivarius K12 and M18 probiotics. In one study, the
number of days that recurrent pharyngotonsillitis-prone children who consume
Bactoblis K12 were on antibiotics (amoxicillin and clavulanic acid) was 30 times lower
than those who did not take the probiotic lozenges.8 Similarly, the number of days this
same cohort of children were on antipyretics (acetaminophen and ibuprofen) was 14
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times lower.8 In addition to an overall reduction in the need for drug treatments, there
were lifestyle impacts as well. Both children and parents respectively missed 93% less
school/preschool and work when children followed the K12 regimen compared to those
who were not treated by the probiotic.8 As antibiotic regimes can be quite costly and
missed work days can pose a financial burden to families, K12 probiotic treatment could
be financially advantageous for at least some pools of patients.
The oral probiotics discussed in this primary research literature review have the
potential to be universally utilized as an alternative to antibiotics and/or other treatments
used to combat and prevent a variety of oral pathologies. As described previously, several
oral afflictions can be significantly reduced in a clinical setting. Of interest, patients
presenting with pharyngitis and/or tonsillitis appear to have a particularly promising K12
treatment outlook based on the data from current literature. Given the present concern
about the development of antibiotic resistance in bacterial species, to help combat this
issue, these probiotics could be used as an alternative treatment to antibiotics in milder
pathogenic infections. Furthermore, since much of the developed world is inextricably
tied to modern medicine practices, implementing the use of probiotics in clinical practice
may prove extremely difficult, but not impossible. For example, many dentists in New
Zealand routinely prescribe K12 and M18 probiotic formulations to prevent dental caries
and to combat mild gingivitis. In recent years, there has been an increase in probiotic
usage within the United States and abroad, which, coupled with the excellent clinical
efficacy demonstrated in a variety of research investigations, bodes well for the future of
the oral probiotics S. salivarius K12 and M18.
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